Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Extended review for Acetadote supplement hits Cumberland shares

This article was originally published in Scrip

Executive Summary

Shares in Cumberland Pharmaceuticals, which have languished since the company broke the deadlock in a recession-hit pharmaceutical sector by raising around $75 million net in an IPO last August, took a further battering yesterday after Cumberland announced a delay in the FDA's review of a new indication for Acetadote (acetylcysteine) injection.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC009967

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel